Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Recruiting now · Phase 3
Conditions studied: Chagas Disease
In brief
Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world. Currently treatment with the only two drugs effective against the infection, benznidazole and nifurtimox, has significant limitations including frequent adverse effects in adult patients. However, timely treatment is key to achieving global objectives of controlling the disease. The standard treatment has a long duration (60 days). NuestroBen will test the hypothesis that shorter treatment regimens of 14 days and 28 days will be non-inferior to the standard 60-day treatment while improving the safety profile.
Key facts
- Study ID
- NCT04897516
- Run by
- Laboratorio Elea Phoenix S.A.
- People needed
- 300
- Starts
- 2021-07-28
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2023-11-30
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fundación Huésped — Buenos Aires, Argentina (enrolling)
- Hospital Francisco Javier Muñiz — Buenos Aires, Argentina (enrolling)
- Instituto de Cardiología de Corrientes "Juana Francisca Cabral" — Corrientes, Argentina (enrolling)
- Centro de Chagas y Patología Regional, Hospital Independencia — Santiago del Estero, Argentina (enrolling)
- Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben" — Buenos Aires, Argentina
- Hospital Donación Francisco Santojanni — Buenos Aires, Argentina
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.